Details
Stereochemistry | MIXED |
Molecular Formula | C18H17ClN2O2 |
Molecular Weight | 328.793 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1CN2CC(=O)NC3=C(C=C(Cl)C=C3)C2(O1)C4=CC=CC=C4
InChI
InChIKey=VCCZBYPHZRWKFY-UHFFFAOYSA-N
InChI=1S/C18H17ClN2O2/c1-12-10-21-11-17(22)20-16-8-7-14(19)9-15(16)18(21,23-12)13-5-3-2-4-6-13/h2-9,12H,10-11H2,1H3,(H,20,22)
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1254
Curator's Comment: Description was created based on several sources, including
http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1254
Oxazolam is a prodrug (precursor) for the benzodiazepine desmethyl-diazepam (nordazepam) and is itself a metabolic product of other benzodiazepines. It has anxiolytic, sedative, and anticonvulsant properties. It is a GABA-A receptor agonist. Oxazolam is marketed in Japan under the brand name Serenal. It is usually used to treat anxiety, tension, depression, and sleeping disorder in neurosis. It is used to treat somatic symptoms in psychosomatic disorders (gastrointestinal diseases, circulatory diseases, endocrine diseases, and autonomic dystonia), anxiety, tension, and depression. It is also used as a preanesthetic medication.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2857046
Curator's Comment: Oxazolam showed no affinity toward benzodiazepine receptor, although it showed moderate in vivo activity. However, its metabolites were found to have both high affinity and in vivo activities. In the case of oxazolam, their metabolites may bind to receptor sites in the brain and then elicit pharmacological action.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0030156 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2857046 |
|||
Target ID: CHEMBL1962 Sources: http://www.t3db.ca/toxins/T3D4651 |
|||
Target ID: CHEMBL4956 Sources: http://www.t3db.ca/toxins/T3D4651 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2899329 |
Primary | Serenal Approved UseSerenal is usually used to treat anxiety, tension, depression, and sleeping disorder in neurosis. It is used to treat somatic symptoms in psychosomatic disorders (gastrointestinal diseases, circulatory diseases, endocrine diseases, and autonomic dystonia), anxiety, tension, and depression. It is also used as a preanesthetic medication. |
||
Primary | Serenal Approved UseSerenal is usually used to treat anxiety, tension, depression, and sleeping disorder in neurosis. It is used to treat somatic symptoms in psychosomatic disorders (gastrointestinal diseases, circulatory diseases, endocrine diseases, and autonomic dystonia), anxiety, tension, and depression. It is also used as a preanesthetic medication. |
Sample Use Guides
General dosage regimen: For adults, take 1 to 2 tablets (10 to 20 mg of the active ingredient) at a time, 3 times daily.
If you take the medicine as a preanesthetic medication, take 1 to 2 mg/kg of the active ingredient before going to bed or the surgery.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
2839
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2104805
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
1V2WI2NA1C
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
OXAZOLAM
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
C166515
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
24143-17-7
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
DTXSID5023401
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
m8296
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
C000425
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
DB15491
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
SUB09508MIG
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
3013
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
2016
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
100000083054
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
4617
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY | |||
|
246-032-0
Created by
admin on Sat Dec 16 18:02:04 GMT 2023 , Edited by admin on Sat Dec 16 18:02:04 GMT 2023
|
PRIMARY |
ACTIVE MOIETY